Talquetamab Combinations Show Promise for Relapsed Multiple Myeloma Patients

Interim results from the phase III MonumenTAL-3 trial indicate that talquetamab-based combinations significantly extend progression-free survival for individuals with relapsed or refractory multiple myeloma. The study, published in The New England Journal of Medicine, compared these regimens against standard treatments. These findings offer encouraging prospects for patients facing this challenging blood cancer.